CD7靶向嵌合抗原受体T细胞治疗60例复发或难治性T细胞急性淋巴细胞白血病及T细胞淋巴母细胞淋巴瘤患者分析
在I/II期临床试验(NCT04572308、NCT04916860)中,60例复发或难治性T细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤患者接受单剂自然选择抗CD7 CAR-T细胞(NS7CAR)治疗,低、中、高三个剂量水平分别为5×10^5/kg、1至1.5×10^6/kg、2×10^6/kg。第28天94.4%患者达骨髓深度完全缓解;2年总生存率和无进展生存率分别为63.5%(95%CI 47.7-79.4)和53.7%(95%CI 38.9-68.6),儿童与成人无差异。
要点
- 第28天94.4%患者达骨髓深度完全缓解,32例髓外病变患者中78.1%有效。
- 2年总生存率63.5%(95%CI 47.7-79.4),无进展生存率53.7%(95%CI 38.9-68.6)。
- 37例缓解后行巩固移植者1年无进展生存率67.2%,高于未移植10例的15.0%(p<.0001)。
核心结论
- NS7CAR-T治疗复发或难治性T细胞急性淋巴细胞白血病及T细胞淋巴母细胞淋巴瘤有效,无进展生存有望,安全性可控。
研究设计与样本
- I/II期临床试验(NCT04572308、NCT04916860)纳入65例儿童和成人复发或难治性T细胞急性淋巴细胞白血病及淋巴母细胞淋巴瘤患者,其中60例接受单剂NS7CAR-T治疗。
- 60例中T细胞急性淋巴细胞白血病35例、T细胞淋巴母细胞淋巴瘤25例;给药剂量分低剂量5×10^5/kg、中剂量1至1.5×10^6/kg、高剂量2×10^6/kg三个水平。
主要发现
- 第28天94.4%患者达骨髓深度完全缓解;32例髓外病变患者中78.1%有效,其中56.3%完全缓解、21.9%部分缓解。
- 2年总生存率63.5%(95%CI 47.7-79.4),2年无进展生存率53.7%(95%CI 38.9-68.6),儿童与成人无差异。
- 37例完全缓解后行巩固移植者1年无进展生存率67.2%(95%CI 51.9-82.4),高于未移植10例的15.0%(95%CI 0-40.2),p<.0001。
- 10例未移植的完全缓解患者中8例复发,2例分别在第128天和第180天维持完全缓解。
- 细胞因子释放综合征发生率91.7%(1/2级80.0%,3/4级11.7%),5%患者出现神经毒性。
关键数值与推荐
- 完全缓解后行巩固移植的37例1年无进展生存率67.2%(95%CI 51.9-82.4),未移植的10例为15.0%(95%CI 0-40.2),p<.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While the use of chimeric antigen receptor-T (CAR-T) therapy for T-cell malignancies is in the early stage of clinical trials, it exhibits substantial potential to offer long-term remission for patients with refractory/relapsed (R/R) T-cell malignancies. In our phase I/II clinical trials, 65 pediatric and adult patients with R/R T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/LBL) were enrolled (NCT04572308 and NCT04916860). Of these, 60 participants (T-ALL 35, T-LBL 25) received a single dose of naturally selected anti-CD7 CAR (NS7CAR) T cells at three levels: a low dose (5 × 105 /kg), a medium dose (1 to 1.5 × 106 /kg), and a high dose (2 × 106 /kg). On day 28, 94.4% of patients achieved deep complete remission (CR) in bone marrow. Among the 32 patients with extramedullary disease, 78.1% showed response, with 56.3% in CR and 21.9% in partial remission. The 2-year overall survival and progression-free survival (PFS) were 63.5% (95% CI 47.7-79.4) and 53.7% (95% CI, 38.9-68.6), with no difference between pediatric and adult patients. PFS was significantly higher among the 37 CR patients who proceeded with consolidation transplant than the 10 patients who did not with 1-year PFS 67.2% (95% CI 51.9-82.4) versus 15.0% (95% CI 0-40.2), p < .0001. Of the 10 CR patients without transplants, eight relapsed, while two sustained CR on day 128, and day 180, respectively. Cytokine release syndrome occurred in 91.7% of patients (grade 1/2 in 80.0%, grade 3/4 in 11.7%) and 5% of patients had neurotoxicity. NS7CAR-T therapy is effective in treating R/R T-ALL/LBL patients with promising PFS while maintaining a manageable safety profile.
引用
- Zhang X, Yang J, Li J, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023. PMID: 37740926. doi:10.1002/ajh.27094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。